Prokineticin 1在结直肠癌组织中的表达及其临床意义

Expression of Prokineticin 1 in Colorectal Cancer Tissues and its Clinical Significance

目的:探讨前动力蛋白1(Prokineticin1)在结直肠癌中的表达及其临床意义。方法:选取2008年5月-2014年12月收治的结直肠癌102例作为研究对象,均行结直肠癌根治术,并将切取的结直肠癌组织作为观察组,同时在手术过程中收集癌旁正常结直肠组织作为对照组。记录患者的一般资料、肿瘤相关情况、Prokineticin1表达情况及预后情况,比较不同临床特征的结直肠癌患者Prokineticin1表达水平,分析影响结直肠癌患者预后的相关因素。结果:观察组Prokineticin1阳性表达率显著高于对照组,比较差异有统计学意义(P<0.001)。不同肿瘤直径、肿瘤分化程度、临床分期及有无淋巴结转移的结直肠癌患者Prokineticin1阳性表达率比较差异有统计学意义(P<0.05)。所有患者出院至随访结束生存10~34个月,中位生存时间为26.4个月,出院后1年、2年、3年生存率分别为90.20%(92/102)、78.43%(80/102)、68.63%(70/102)。肿瘤低分化、临床分期Ⅲ~Ⅳ期、出现淋巴结转移和Prokineticin1阳性的结直肠癌患者3年生存率显著降低(P<0.05)。多因素Cox比例风险回归模型结果显示,肿瘤低分化、临床分期Ⅲ~Ⅳ期、出现淋巴结转移和Prokineticin1阳性为影响结直肠癌患者预后的独立危险因素(P<0.05)。结论:Prokineticin1表达阳性为影响结直肠癌患者预后的独立危险因素,可作为临床评估结直肠癌患者病情进展和预后的指标之一。

Objective To investigate the expression of Prokineticin 1 (PROK 1) in colorectal cancer (CRC)and its clinical significance. Methods A total of 102 patients with CRC admitted to our hospital from May 2008 to December 2014 were enrolled as research subjects, and underwent radical resection of CRC. The resected CRC tissues were taken as the observation group, and the adjacent normal tissues were collected intraoperatively as the control group. General information, tumor-related information, expression level of PROK 1 and prognosis were recorded, and expressions of PROK 1 in CRC patients with different clinical features were compared. Results The positive expression rate of PROK 1 in CRC tissues was higher than that in adjacent normal tissues, and the difference was statistically significant ( P < 0.001). There was significant difference in positive expression rate of PROK 1 in CRC patients with different tumor diameters,tumor differentiation, clinical stage and presence of lymph node metastasis ( P <0.05). All patients survived for 10 to 34 months from hospital discharge to the end of follow-up, with a median survival of 26.4 months. The 1-, 2-, and 3-year survival rates after discharge were 90.20%(92/102) and 78.43%(80/102), and 68.63%(70/102), respectively. The 3-year survival rate of CRC patients with poor tumor differentiation, clinical stage Ⅲ-Ⅳ, lymph node metastasis and positive expression of PROK 1 was significantly lower ( P <0.05). The multivariate Cox proportional hazards regression model showed that the poor tumor differentiation, stage III-IV, lymph node metastasis and positive expression of PROK 1 were independent risk factors for the prognosis of patients with CRC ( P <0.05). Conclusion Positive expression of PROK 1 is an independent risk factor for the prognosis of CRC patients. Therefore, it can be used as one of the indicators for clinical evaluation of disease progression and prognosis in patients with CRC.